Accueil » La R&D d'Unicancer » Les publications de la R&D d'Unicancer » Les publications

Publications de la R&D d'Unicancer

2015

Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial.

Gravis G et al., Eur Urol. 2015 Nov 21. pii: S0302-2838(15)01103-3. doi: 10.1016/j.eururo.2015.11.005.

2015

Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer.

Ladoire S et al., Autophagy. 2015 Oct 3;11(10):1878-90. doi: 10.1080/15548627.2015.1082022.

2015

Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.

Forbes JF,. Lancet. 2015 Dec 11. pii: S0140-6736(15)01129-0. doi: 10.1016/S0140-6736(15)01129-0.

2015

Coexpression of androgen receptor and FOXA1 in nonmetastatic triple-negative breast cancer: ancillary study from PACS08 trial.

Guiu S et al., Future Oncol. 2015;11(16):2283-97. doi: 10.2217/fon.15.102.

2015

UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer.

Gonçalves A et al. Ann Oncol. 2015 Aug;26(8):1692-7. doi: 10.1093/annonc/mdv216. Epub 2015 May 5

2014

Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER).

Lancet Oncol. 2014 Mar;15(3):267-74

2014

Radiation plus docetaxel and cisplatin in locally advanced pancreatic carcinoma: a non-comparative randomized phase II trial

Dig Liver Dis. 2014 Oct;46(10):950-5

2014

Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial.

Lancet Oncol. 2014 Mar;15(3):305-14.

2014

Results in the elderly with locally advanced rectal cancer from the ACCOR12/PRODIGE 2 phase III trial: tolerance and efficacy.

Radiother Oncol. 2014 Jan;110(1):144-9

2014

Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.

Lancet Oncol. 2014 Dec;15(13):1442-50)